Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT02985021
Terminated
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/03/2021
Locations: VA Greater Los Angeles - West LA, Los Angeles, California +2 locations
Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Register for Updates
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
NCT01505868
Completed
This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment with hormones. Drugs used in chemotherapy, such as cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving c... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/29/2021
Locations: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Register for Updates
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
NCT00003816
Completed
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known which combination chemotherapy regimen is most effective when given before a d... Read More
Gender:
ALL
Ages:
Between 4 years and 70 years
Trial Updated:
07/19/2021
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02367781
Completed
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2021
Locations: Highlands Oncology Group, Springdale, Arkansas +131 locations
Conditions: Carcinoma, Non-Squamous Non-Small Cell Lung
Register for Updates
Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
NCT00072384
Completed
Phase III trial to determine the effectiveness of combining systemic chemotherapy and subtenon carboplatin with ophthalmic therapy in treating children who have intraocular retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether systemic chemotherapy and subtenon (under the conjunctiva of the eye) carboplatin combined with ophthalmic therapy is ef... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
07/12/2021
Locations: Children's Oncology Group, Arcadia, California +10 locations
Conditions: Intraocular Retinoblastoma
Register for Updates
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
NCT00499616
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma cells become more like normal cells, and grow and spread more slowly. Giving combination chemotherapy before surgery may make the tumor smaller and make it more likely that the tumor can be surgically removed. It is not yet... Read More
Gender:
ALL
Ages:
12 years and below
Trial Updated:
07/01/2021
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +188 locations
Conditions: Neuroblastoma
Register for Updates
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01711697
Unknown
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used i... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/22/2021
Locations: Grady Health System, Atlanta, Georgia +3 locations
Conditions: Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NCT00528437
Completed
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid has on children and adolescents with recurrent/refractory brain tumors Find out how the body uses 13-cis-retinoic acid by studying the your blood levels and proteins in the blood that break down the 13-cis-retinoic acid Determine how well 13-cis-retinoic acid penetrate... Read More
Gender:
ALL
Ages:
Between 6 months and 21 years
Trial Updated:
06/17/2021
Locations: Phoenix Children's Hospital, Phoenix, Arizona +16 locations
Conditions: Brain Tumors
Register for Updates
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
NCT02435680
Completed
To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/26/2021
Locations: Highlands Oncology Group, Fayetteville, Arkansas +22 locations
Conditions: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Register for Updates
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
NCT02190695
Completed
The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2021
Locations: Temple BMT Program at Jeanes Hospital, Philadelphia, Pennsylvania +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Register for Updates
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
NCT02413320
Completed
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2021
Locations: University of Kansas Cancer Center - CRC, Fairway, Kansas +8 locations
Conditions: Triple-negative Breast Cancer
Register for Updates
Locally Advanced NSCLC Hyperfractionated RT
NCT03128008
Completed
This is a prospective phase II study designed to evaluate an accelerated and adaptive RT approach for locally-advanced non-small cell lung cancer (NSCLC). All eligible subjects will have an interim PET-CT during radiation therapy to determine the metabolic complete response rate. Radiation therapy will be given in an accelerated fashion (2 Gy/fraction, 6 fractions/week) with concurrent chemotherapy. Interim responses will be assessed using PERCIST criteria. Despite concurrent chemotherapy and r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2021
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Carcinoma, Non Small Cell Lung (NSCLC)
Register for Updates